# A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

> **NCT03668496** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 390 (actual)

## Conditions studied

- Lung Cancer Squamous Cell
- Lung Cancer Stage IV
- PD-1 Antibody
- Chemotherapy Effect

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** The placebo

## Key facts

- **NCT ID:** NCT03668496
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-09
- **Primary completion:** 2020-11-06
- **Final completion:** 2021-12-31
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03668496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03668496, "A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03668496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*